Pasithea Therapeutics Corp. is a biotechnology company specializing in the research and development of advanced therapeutics for psychiatry and neurology. The company's primary focus lies in discovering innovative solutions for mental health disorders, leveraging cutting-edge science and technology to address unmet medical needs. Pasithea Therapeutics aims to transform the treatment landscape for conditions such as depression, anxiety, and other psychiatric disorders. Driven by a mission to revolutionize mental health care, Pasithea Therapeutics engages in developing proprietary drug candidates and exploring the potential of psychedelic compounds. The company operates within the broader healthcare and biopharmaceutical sectors, contributing to significant advancements in medical research and treatment modalities. Its innovative approach positions it at the forefront of a rapidly evolving industry that seeks to tackle complex mental health challenges. Pasithea Therapeutics is notably committed to expanding therapeutic options, providing an impactful presence in the market as healthcare systems globally strive to enhance mental health outcomes. Through collaboration with research institutions and strategic partnerships, the company plays a vital role in pushing the boundaries of medical science for psychiatry and neurology.